Previous 10 | Next 10 |
Theratechnologies press release (NASDAQ:THTX): Q1 Net Loss of $9.03M Revenue of $18.56M (+20.3% Y/Y) misses by $3M. 2022 Revenue Guidance: The company affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022 vs consensus of $81.82M, or growth of ...
- Q1 2022 consolidated sales grew 20%, supported by 35% growth in EGRIFTA SV ® sales - TH1902 Phase 1/Part A enrollment at 300 mg/m 2 dose nearing completion, potentially enabling recruitment of larger Phase 1/Part B expansion (basket trial) in the...
Two Additional Preclinical Proof-of-concept Posters in Ovarian and Metastatic Lung Cancer Models Also Presented at the Meeting MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: TH...
MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter...
MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three p...
Theratechnologies Inc. (THTX) Q4 2021 Earnings Conference Call February 24 2022 8:30 AM ET Company Participants John Mullaly - IR, LifeSci Advisors Paul Levesque - President and Chief Executive Officer Philippe Dubuc - SVP and Chief Financial Officer Christian Marsolais - SVP and Chief Medica...
Theratechnologies press release (NASDAQ:THTX): Q4 GAAP EPS of -$0.34 misses by $0.26. Revenue of $18.75M misses by $1.73M. For further details see: Theratechnologies GAAP EPS of -$0.34 misses by $0.26, revenue of $18.75M misses by $1.73M
- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV ® sales - Second half fiscal 2021 revenues grew 10% over 2020, while total new enrollments grew 24% as commercial execution strategy firmly carries momentum into 2022 - Lead onc...
No difference in pharmacokinetics between IV Push and IV Infusion No serious adverse events observed No difference in viral load between IV Push and IV Infusion and no anti-drug antibodies detected MONTREAL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Theratechnologies I...
- Top Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies’ from its current partner contract sales organization - Higher employee engagement and retention, greater ability to attract top talent and lower tur...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...